OLYMPIA-5 (NCT-TBC) PHASE 3

Study of investigational odronextamab + lenalidomide in patients with **relapsed or refractory follicular lymphoma or marginal zone lymphoma**

Primary Objective: evaluate the efficacy and safety of odronextamab + lenalidomide vs rituximab + lenalidomide in patients with R/R FL or R/R MZL

PATIENTS WITH R/R FL OR R/R MZL (N≈325 R/R FL; N≈70 R/R MZL)

OPEN LABEL INTERVENTION

Part 1: non-randomized

Odronextamab safety run-in

Part 2: randomized

R 1:1

Arm 1

Odronextamab (IV) + lenalidomide

Arm 2

Rituximab + lenalidomide

Primary Endpoint

Progression-free survival[a]

Secondary Endpoints

Complete response rate
Best overall response
Overall survival

FIND OUT MORE

Scan here to find out more about this study at https://clinicaltrials.gov/ct2/show/NCT-TBC

This information is intended for investigators interested in open clinical trials.
Odronextamab is an investigational agent and has not been evaluated by any regulatory authority.

[a]Based on Independent Central Review (ICR).
FL, follicular lymphoma; IV, intravenous; MZL, marginal zone lymphoma; N, number of patents; R randomized; R/R, relapsed or refractory

REGENERON®
MEDICAL AFFAIRS

OLYMPIA-5 (NCT-TBC) **PHASE 3**

ODRONEXTAMAB

An Investigational CD20xCD3 Bispecific Antibody

Simultaneously engages CD20 on malignant B cells and CD3 on cytotoxic T cells[1]

SELECTED INCLUSION CRITERIA[a]

- Histologically confirmed FL Grade 1–3a or MZL (nodal, splenic, or extra nodal)
- ≥1 Refractory disease or relapsed after ≥ 1 prior systemic therapy including an anti-CD20 antibody
- Measurable disease
- ≤2 ECOG PS ≤2

SELECTED EXCLUSION CRITERIA[a]

- CNS lymphoma
- Histological evidence of transformation to high grade or diffuse large B-cell lymphoma
- Prior use of lenalidomide or any CD20xCD3 bispecific antibody within 6 months

For more information, visit www.clinicaltrials.gov or please call [+353 (0)61 533 400 OR 844 REGN-MID].
NCT
https://clinicaltrials.gov/ct2/show/NCT-TBC

This information is intended for investigators interested in open clinical trials.
Odronextamab is an investigational agent and has not been evaluated by any regulatory authority.

[a]Inclusion/exclusion criteria include a summary of selected criteria. Please review the complete study design on clinicaltrials.gov for complete details.

CD, cluster of differentiation; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index.

Current per clinicaltrials.gov as of Month day, 2023.

[1]Smith EJ et al. *Sci Rep*. 2015;5:17943
Veeva code November 2023.

REGENERON®
MEDICAL AFFAIRS